Published Date:2021-12-30 Original Link:https://www.onenessbio.com/en/news_detail133_1.htm No 2 Date of announcement 2021/12/30 Time of announcement 17:26:58 Subject Annouce the change of the spokesperson. To which item it meets paragraph 8 Date of events 2021/12/30 Statement Type of personnel changed (please enter: spokesperson, acting spokesperson, important personnel (CEO, COO, CMO, CSO, etc.), financial officer, accounting...Read More
Published Date:2021-12-30 Original Link:https://www.onenessbio.com/en/news_detail132_1.htm No 1 Date of announcement 2021/12/30 Time of announcement 17:22:03 Subject Oneness announces the information about the investor’s conference of 2021 Q4. To which item it meets paragraph 6 Date of events 2021/12/30 Statement Date of the board of directors resolution or date of occurrence of the change:2021/12/30 Position (Please enter...Read More
Date 2021/12/29 Location Online Presentation Download Download Chinese Version Download English Version Video Recording (English interpretation) Note N/ARead More
Published Date:2021-12-22 Original Link:https://www.onenessbio.com/en/news_detail131_1.htm No 1 Date of announcement 2021/12/17 Time of announcement 16:33:29 Subject Oneness announces the information about the investor’s conference of 2021 Q4. To which item it meets paragraph 12 Date of events 2021/12/29 Statement Date of institutional investor conference:2021/12/29 Time of institutional investor conference:15:00 (GMT+8) Location of institutional investor conference:Online Investor...Read More
Published Date:2021-12-17 Original Link:https://www.onenessbio.com/en/news_detail130_1.htm No 1 Date of announcement 2021/12/17 Time of announcement 17:37:36 Subject The Singapore Health Science Authority has accepted the NDA application of the diabetic foot ulcer new drug, Fespixon To which item it meets paragraph 53 Date of events 2021/12/17 Statement 1.Product:ON101 Diabetic foot ulcer new drug 2.Mass...Read More
Published Date:2021-12-16 Original Link:https://www.onenessbio.com/en/news_detail129_1.htm No 1 Date of announcement 2021/12/16 Time of announcement 17:19:51 Subject Oneness Biotech Co., LTD. receives “Prior Authorisation for Import of Traditional Medicines” from Macau on Fespixon cream (Research code: ON101) To which item it meets paragraph 53 Date of events 2021/12/16 Statement 1.Date of occurrence of...Read More
Published Date:2021-12-13 Original Link:https://www.onenessbio.com/en/news_detail128_1.htm No 1 Date of announcement 2021/12/12 Time of announcement 16:56:09 Subject The partial efficacy data for the Phase 2a study of FB825 in the treatment of atopic dermatitis in the U.S. have been analyzed To which item it meets paragraph 10 Date of events 2021/12/11 Statement 1.Product:FB825 anti-CεmX humanized...Read More
Published Date:2021-12-03 Original Link:https://www.onenessbio.com/en/news_detail127_1.htm No 1 Date of announcement 2021/12/03 Time of announcement 16:56:09 Subject The mechanism of action and Phase 3 MRCT results of the diabetic foot ulcer new drug, Fespixon have been accepted for an oral presentation at IDF Congress 2021 To which item it meets paragraph 12 Date of events 2021/12/03 Statement...Read More
Published Date:2021-12-02 Original Link:https://www.onenessbio.com/en/news_detail126_1.htm No 1 Date of announcement 2021/12/01 Time of announcement 18:25:04 Subject Oneness Biotech Co., Ltd. receives a Taiwan patent O titled “TOPICAL FORMULATION FOR PROMOTING WOUND HEALING” O on Fespixon cream (Research code: ON101). To which item it meets paragraph 53 Date of events 2021/12/01 Statement 1.Date of occurrence...Read More
